KAHR Medical Overview
KAHR is developing immuno-oncology drug candidates for the treatment of multiple types of cancer. Its lead product, DSP107, is a CD47x41BB targeting compound that simultaneously targets cancer cells, weakens their innate defenses, and activates an effective local response of both innate and adaptive immunity. KAHRs technology platform is based on multifunctional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells to selectively target and bind to the tumor. MIRPs bridge cancer cells to immune cells to produce a targeted synergistic effect by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response while recruiting the adaptive immune system to bind and selectively kill the cancer cells. In August 2020, KAHR Medical received FDA clearance to begin clinical trials on its immunotherapy drug to battle cancer.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
/PRNewswire/ -- KAHR, a clinical-stage biotech company developing DSP107, a first-in-class bi-specific 4-1BB T-cell engager that activates innate and adaptive...
KAHR, a clinical-stage biotech company, announced positive results from the Phase 2 dose expansion cohort of DSP107 in combination with atezolizumab for treating 3rd line microsatellite stable metastatic colorectal cancer (MSS-CRC). The combination therapy has shown anti-tumor activity and extended survival, including in patients with liver metastases. These results will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. DSP107 is a bi-specific 4-1BB T-cell engager that activates both innate and adaptive immunity, targeting CD47 overexpression on cancer cells. This approach is particularly relevant for MSS-CRC, a challenging subtype of colorectal cancer. KAHRs development of DSP107 aims to address the unmet medical need in treating MSS-CRC.
Product StageFDA approved/pending approval
growth-positive
KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors
KAHR, a clinical-stage biotech company, announced positive results from a Phase I study of its novel immunotherapy, DSP107, in combination with atezolizumab. The study, which focused on patients with advanced solid tumors, demonstrated significant tumor shrinkage and durable responses, particularly in patients with microsatellite stable colorectal cancer (MSS-CRC). The highest dose of DSP107 was selected for Phase II expansion cohorts, showing a disease control rate of 57%. The treatment was well tolerated with no dose-limiting toxicities. These promising results will be presented at the ASCO 2023 Annual Meeting. KAHRs DSP107 targets CD47 and 4-1BB, activating both innate and adaptive immunity to treat solid tumors and blood cancers.
growth-positive
MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma
KAHR Medical has received an investment from the Myeloma Investment Fund (MIF) to explore the potential of its leading immunotherapy drug candidate, DSP107, for the treatment of multiple myeloma. The investment reinforces KAHRs commitment to developing innovative treatment approaches for myeloma patients. With this investment, KAHR Medical has raised a total of $59 million since June 2021. DSP107 is a dual-targeting fusion protein that activates innate and adaptive immunity to bolster anti-tumor immunity. It has demonstrated a good safety profile and high disease control rates in a phase 1 trial. MIF is a venture philanthropy fund that invests in promising companies and technologies in oncology to drive the development of new therapies for multiple myeloma.
Investment
growth-positive
KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
KAHR and Cancer Focus Fund have announced the dosing of the first patient in a Phase 1b clinical trial of DSP107, a CD47x41BB targeting fusion protein, in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The trial is being funded by an investment from Cancer Focus Fund. KAHRs CEO, Yaron Pereg, expressed gratitude for the support and highlighted the potential of DSP107 to achieve significant anti-tumor effects across cancer types. The trial is being conducted at MD Anderson and led by Naval Daver. DSP107 is also being tested in a Phase 1/2 clinical trial for solid tumor cancers. KAHR develops novel dual-targeting fusion protein therapeutics that activate both the innate and adaptive immune systems.
Investment
growth-positive
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Cancer immunotherapy company KAHR has announced the first closing of an investment round, raising $46.5 million. The financing, led by aMoon, will be used to advance the clinical development of the companys lead product candidate, DSP107, a CD47x41BB targeting fusion protein for the treatment of solid and blood cancers. The funding will also support the development of KAHRs preclinical pipeline. The successful financing round includes participation from new and existing investors. KAHRs unique approach to cancer immunotherapy aims to unmask cancer cells for immune recognition and trigger a targeted activation of anticancer immunity. The companys lead product candidate, DSP107, is currently being tested in Phase 1/2 studies. KAHRs technology platform utilizes multi-functional immuno-recruitment proteins to selectively target and bind to tumors.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $117.5M |
| Last funding | Undisclosed |
| Stage | F |
| Rounds | 12 |
| Investors | 17 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | kahrbio.com/ |
Locations
Dam HaMacbim St 28, Modi'in-Maccabim-Re'ut, Israel
Photos & Videos
1 item(s)
